Pharmasimple SA Overview
Pharmasimple was a Belgian online parapharmacy that, between 2010 and 2021, built one of the larger French-language e-commerce businesses for dermo-cosmetics, hygiene, food supplements and other non-prescription health and beauty goods, selling overwhelmingly into France from a logistics base in Wallonia. A roll-up of two French platforms — Parapharmazen (2018) and Enova Santé's 1001Pharmacies.com (2019) — and the COVID-19 demand spike lifted revenue to a record EUR 45.2M in 2020, but the business remained structurally low-margin and cash-hungry. After demand normalised in 2021, management abandoned the pure-play model in favour of acquiring brick-and-mortar Belgian pharmacies, financed largely by convertible instruments and loans from Alpha Blue Ocean's Global Tech Opportunities 12 fund. The pivot failed: the online platforms were sold in late 2022, the pharmacy network shrank, financing was withdrawn in May 2023, and the company was declared bankrupt in June 2023. It is now a shell in liquidation.
Company's own description (latest available)
The company's final boilerplate (January–May 2023 press releases) described Pharmasimple as a distribution group specialising in the sale of pharmaceutical and parapharmaceutical products, operating a network of pharmacies in Belgium (described as "about fifteen" in January 2023 and "about ten" in May 2023), with the ambition of becoming one of the leaders of its sector in Belgium through an aggressive external-growth programme. Pharmasimple never published a full-length annual report in English or a risk-factor-style business section; the only formal descriptive document located is the FSMA-filed information note of 18 November 2019, which describes the issuer as the owner of the pharmasimple.com website since its incorporation.
Earlier boilerplate (2017–2022) described the company as a specialist in online parapharmacy, "one of the main players in France", offering more than 120,000 product references in cosmetics, dermo-cosmetics, medical accessories and food supplements, holding Bpifrance's "Entreprise innovante" label, and aiming to become a European sector leader.
Independent characterisation
| Phase | Period | Model | Revenue model | Value-chain position |
|---|---|---|---|---|
| 1. Online pharmacy start-up | 2010–2013 | Website initially selling general pharmacy medicines | Product resale (retail margin) | Online retailer |
| 2. Online parapharmacy pure-play and roll-up | 2013–2021 | Refocused on parapharmacy (non-medicine health & beauty) because medicine margins were poor; acquired Parapharmazen and 1001Pharmacies; some B2B product sales | ~100% product resale; 1001Pharmacies brought a marketplace (commission) dimension; no subscription or licensing revenue disclosed | Downstream online retailer/marketplace buying from laboratories/wholesalers and shipping to consumers, primarily in France |
| 3. Omnichannel / pharmacy network | Dec 2021–May 2023 | Acquisition of Belgian community pharmacies (mostly rural), concept store and in-store kiosks, real-estate sub-holding for pharmacy premises; online platforms divested in late 2022 | Product resale in pharmacies (OTC, prescription dispensing, parapharmacy) | Brick-and-mortar retail pharmacy operator |
Across its life Pharmasimple ran three successive business models:
Customer types and end-markets. B2C consumers in France (about 90% of sales in 2017, per Euronext's listing profile) and Belgium/Benelux; a minor B2B product channel was referenced in 2020. At its 2016–2017 listing, the company claimed more than 300,000 customers and roughly 120,000 orders a year across 770 brands. End-markets: French and Belgian parapharmacy (dermo-cosmetics, hygiene, mother & baby, supplements, veterinary), then Belgian community pharmacy.
Economic character. Pharmasimple was a price-led, search-traffic-dependent reseller with thin gross margins (14.5% of sales in H1 2020, 10.8% in H1 2021, per half-year releases) and high marketing and logistics costs. The model only produced positive EBITDA in the single COVID-boosted year of 2020 (EBITDA EUR 1.0M on EUR 45.2M sales). Gross margin improved to about 20% in H1 2022 as pharmacies were consolidated, but restructuring costs and stock write-downs overwhelmed it.
Strategy
Stated strategy themes (in the company's own framing, paraphrased)
- 2016–2019 — "Build-up" leadership in French online parapharmacy: grow organic SEO traffic, develop own brands, and consolidate the fragmented online market through acquisitions; ambition to be a European leader.
2019 — "Pharmasimple 2023" plan: referenced in the February 2020 release as a plan to be presented with the FY2019 results; return to operating breakeven targeted in 2020. The plan's detailed targets were not captured in the sources reviewed.
December 2021 — Complete business-model overhaul: shift to an online/offline mix to cut marketing spend, reduce dependence on paid traffic, and add recurring revenue and advice-driven margin through pharmacies; concept store with kiosks.
2022 — Pharmacy network: acquire at least 15 pharmacies in 2022 and build a group of 150–200 pharmacies within five years; combine Pharmasimple's procurement and logistics expertise with local pharmacist advice; real-estate sub-holding for pharmacy premises; the CEO framed this as turning the stock into a more defensive investment.
2023 — Restructure, deleverage, then resume acquisitions: cut staff, dispose of non-core activities, clear liabilities, restart pharmacy acquisitions once total debt was back near EUR 1M.
Initiatives announced in the final 24 months before bankruptcy (May 2021 – May 2023)
| Date | Initiative | Target / metric | Outcome |
|---|---|---|---|
| Aug 2021 | EUR 10M OCABSA programme with GTO 12 | Fund working capital and growth without immediate large dilution | Drawn in tranches; ended with funding withdrawal in May 2023 |
| 2,021 | Concept store and kiosks | Reach traditional customers with online functionality | No metrics disclosed |
| Dec 2021 | Strategic overhaul | Online/offline mix from 2022 | Executed, then failed |
| Mar 2022 | Bank debt cleared | Zero bank debt by end of Q1 2022 | Achieved per company |
| Mar 2022 | First 5 pharmacies | ~EUR 7M annual revenue; ~EUR 0.7M EBITDA contribution | Integrated May 2022 |
| May 2022 | Pharmacies 8–12 | 7 pharmacies to deliver EUR 8.7M first full-year revenue; 4 more ~EUR 5M | Partly integrated; 4 deferred to mid-2023 |
| Jul 2022 | Pharmasimple Immo | Hold pharmacy premises | — |
| Oct 2022 | Confirmation of ≥15 pharmacies in 2022 | — | 14 reported by July 2022; about 15 by Jan 2023 |
| Dec 2022 | Reverse split | Clean up share register; holders under 50,000 old shares cashed out | Executed 12 Dec 2022 |
| Dec 2022–Jan 2023 | Sale of Pharmasimple.com and Parapharmazen.com | Exit loss-making online activities | Completed; buyer and price not publicly disclosed |
| Jan 2023 | EUR 5.64M GTO 12 loan | Finish restructuring, honour short/medium-term obligations | Funding stopped in May 2023 |
| Jan 2023 | 2023 guidance | ~EUR 6M revenue; operating profitability for continuing (pharmacy) operations | Not achieved — bankruptcy |
ESG commitments, cost-programme savings targets and medium-term margin targets: not publicly disclosed.
Products & Services
Pharmasimple was a reseller; it did not manufacture. Product detail below is drawn from company boilerplate, listing documents, aggregator business descriptions and press releases.
E-commerce platforms (Online segment, 2010–2022)
| Platform | Description | Target customer | Launch / acquisition | Pricing model | Fate |
|---|---|---|---|---|---|
| Pharmasimple.com | Flagship online parapharmacy; 120,000 references across ~770 brands (2017). Organic search traffic to the site rose 167% in H1 2020 | French and Benelux consumers | Launched 2010 | Discount retail pricing; "PharmaDeals" offers and "My Pharmasimple" loyalty discounts are referenced in current third-party profiles | Sold, finalised by Jan 2023 (buyer not publicly disclosed) |
| Parapharmazen.com | Generalist French online parapharmacy, described as the 4th-largest French site | French consumers | Acquired Apr 2018 | Retail | Sold, finalised by Jan 2023 |
| 1001Pharmacies.com (Enova Santé) | Marketplace connecting consumers and sellers; ~90% of its traffic from SEO at acquisition. A 2014–2016 French court case had already barred it from selling medicines online (CNOP v. Enova Santé), confining it to parapharmacy | French consumers | Acquired Jan 2019; consolidated Apr 2019 | Marketplace / retail | Fate pending in Q1 2023; outcome not publicly disclosed |
Product categories sold online (as described by data providers and the company)
| Category | Examples | Notes |
|---|---|---|
| Beauty & dermo-cosmetics | Face cleansing and care, make-up, hair removal, body care, tanning, hair treatments, perfume | Core traffic driver; brands referenced on profiles include Clinique among others |
| Health | Feminine hygiene, dental hygiene, alternative medicine, hearing aids, aromatherapy | Non-prescription |
| Men's care | Face, body, hair care; shaving | — |
| Diet & nutrition | Diet products, sports nutrition, supplements, health food, meal replacements | High-recurrence category emphasised in 2016 |
| Mother & baby | Nappies, baby washing, breastfeeding equipment, baby food, baby care | — |
| Veterinary & pest control | Pet health products | — |
| Medical accessories | Listed in boilerplate | — |
| Own brands | In 2016 the company said it intended to develop its own innovative product brands | No own-brand launch was ever disclosed |
Offline / omnichannel offerings (2021–2023)
| Offering | Description | Launch | Status |
|---|---|---|---|
| Pharmasimple Concept Store | Physical store with interactive kiosks bringing internet functionality to traditional customers | 2,021 | Not publicly disclosed after 2022 |
| Pharmasimple-affiliated pharmacies | Acquired community pharmacies rebranded with Pharmasimple signage and plugged into group purchasing; personalised advice, OTC and prescription dispensing, parapharmacy | From Mar 2022 | In liquidation |
| PharmaDeals / My Pharmasimple loyalty | Exclusive offers and loyalty discounts (referenced on current third-party profiles) | — | — |
Pricing schedules, unit economics per channel and average basket were never disclosed.
Financial Narrative
Basis of preparation. Figures come from company press releases (consolidated, some unaudited), Belgian statutory accounts as summarised by registry aggregator Signumi (FY2021, likely non-consolidated), and — for net margins FY2017–FY2020 — an aggregator (Rendementbourse) whose figures could not be reconciled with primary documents and are flagged accordingly. No audited FY2022 or FY2023 accounts were published. Blank cells = not publicly disclosed.
Income statement
Sources: FY2017–FY2018 revenue, results release 26 Apr 2019; FY2019 revenue, release 5 Feb 2020; FY2019–FY2020 EBITDA and FY2020 revenue, results release 14 Apr 2021; FY2021 revenue, release 23 Feb 2022 (company: EUR 30.0M; statutory accounts: EUR 29.9M); FY2021 EBITDA (EUR –4.59M) and net loss (EUR –8.94M), Belgian statutory accounts via Signumi; FY2017–FY2020 net margin, Rendementbourse; FY2021 net margin computed. The FY2020 results release states the net loss was significantly reduced versus FY2019, consistent with the aggregator's direction. No dividend was ever paid.
Revenue CAGR: FY2017–FY2021 = 12.1% p.a. (EUR 19.0M → EUR 30.0M); FY2018–FY2020 = 64.0% p.a. (acquisitions + COVID); FY2015–FY2020 = 46.0% p.a. (EUR 6.8M → EUR 45.2M). Computed from the figures above.
Half-year detail (the most granular disclosure available)
Sources: releases of 21 Jul 2020, 25 Feb 2021, 28 Jul 2021, 7 Oct 2021, 23 Feb 2022, 11 Oct 2022; Cercle Finance 8 Oct 2021; Signumi (FY2021 cash). Discrepancies: H1 2021 revenue is shown as EUR 15.9M (Jul 2021 release) and EUR 16.0M (Oct 2021 results); end-2020 net debt is EUR 5.2M (FY2020 results) versus EUR 5.3M (H1 2021 results comparator). H1 2022 revenue is EUR 13.6M in the October results versus EUR 14.7M in the July revenue release.
Balance sheet
Sources: FY2020 results release (equity EUR 5.5M; accounting net debt EUR 5.2M including a EUR 3.9M bond issued for the 1001Pharmacies acquisition); FY2021 statutory accounts via Signumi (total assets EUR 18.19M, debt EUR 14.00M, cash EUR 1.12M, equity EUR 4.14M); company restructuring updates of 9 Feb, 7 Mar and 11 Apr 2023 (net debt and payables at 31 Dec 2021, 31 Dec 2022, 28 Feb and 31 Mar 2023; equity EUR 4.1M → 3.8M → 2.0M → 1.9M). The short/long-term split of debt was not publicly disclosed. Non-current liabilities rose by EUR 3.9M in H1 2019 because of the 1001Pharmacies acquisition financing (H1 2019 results, 18 Oct 2019).
Cash flow
Sources: FSMA decision (EUR 5M capital increase closed 4 Dec 2019); release 27 Aug 2019 (EUR 0.5M loans); releases 30 Aug 2021 and 27 Jan 2023. Cash-flow statements were never published in press releases. A short-term credit line top-up of EUR 1.7M by end of May 2022 was also referenced (release 3 Mar 2022).
Ratios (computed where inputs exist)
Sources: FY2021 liquidity, solvency and gearing ratios from Signumi; ROE, ROA, asset turnover, revenue per FTE and FY2020 net debt/EBITDA computed from figures in 6.1–6.3. FY2021 net debt/EBITDA is not meaningful (negative EBITDA).
Commentary on trends, inflections and drivers
2017–2018: contract loss masks underlying growth. Revenue fell from EUR 19.0M to EUR 16.8M in 2018 because a distribution contract with a large European laboratory signed in 2017 was not renewed; excluding it, management claimed 22% pro forma growth, driven by rising natural (SEO) traffic. The year was loss-making (H1 2018 net loss EUR 1.1M) as the company invested in its website and a new logistics building and absorbed Parapharmazen.
2019: acquisition-led scale, chronic liquidity strain. Revenue jumped 67% to EUR 28.1M (around 40% excluding the 1001Pharmacies contribution, per the February 2020 release), but EBITDA stayed negative (EUR –1.3M). The FSMA's 2025 decision provides an unusually candid view of the period: early 2019 combined rising sales with heavy losses, growing cash needs, large supplier arrears and strained supplier relations; every external investor approached in spring 2019 declined. The company survived on EUR 0.5M of shareholder bridge loans and a deeply discounted EUR 5M rights-style capital increase in which the founder's group took 71% of the new shares.
2020: the COVID peak. Lockdowns pushed H1 2020 revenue up 111% to EUR 30.2M; full-year sales reached EUR 45.2M and EBITDA turned positive at EUR 1.0M — the only positive EBITDA year in the company's listed history. Fixed costs rose only EUR 0.7M (+23%) as volume absorbed overhead. Even so, EBITDA margin was just 2.2%, revealing how little operating leverage the model had.
2021: reversal and cash burn. With demand normalising, H1 2021 sales fell 47%, gross margin compressed from 14.5% to 10.8% as the company leaned on paid search (SEA) to defend volumes, and net debt rose to EUR 7.4M by June. Full-year statutory accounts show EBITDA of EUR –4.6M and a net loss of EUR –8.9M — the net loss was nearly 30% of revenue. Equity of EUR 4.1M against EUR 14.0M of debt left a solvency ratio of 22.8%. The September 2021 convertible facility with GTO 12 was the lifeline.
2022: the pivot that destroyed the remaining value. The company used convertible-bond proceeds to clear bank debt and buy pharmacies. Gross margin improved to roughly 20% in H1 2022, but online revenue fell to EUR 10.8M (–32%), EBITDA worsened to EUR –3.6M (including large reorganisation costs), and stock write-downs pushed the half-year operating loss to EUR –6.0M. By year-end the online platforms were sold, more than 50 of 65 employees had left, and equity was EUR 3.8M.
2023: collapse. Equity halved again to EUR 1.9M by March 2023 as some pharmacy acquisitions were unwound. Management projected about EUR 6M of 2023 revenue from the remaining pharmacies. When GTO 12 stopped funding in early May 2023, the company declared itself insolvent within days.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Role | Status |
|---|---|---|---|
Pharmasimple SA | Belgium | Listed parent; operated pharmasimple.com until late 2022; owner of pharmacy businesses | Bankrupt (Jun 2023) |
Parapharmazen (platform/company) | France | Online parapharmacy (4th-largest French site at acquisition, per FSMA) | Platform sold late 2022 (buyer not publicly disclosed) |
Enova Santé SAS | France (Lunel/Montpellier area) | Publisher of marketplace 1001Pharmacies.com | Fate "to be determined" in Q1 2023; outcome not publicly disclosed |
Pharmasimple Immo | Belgium | Real-estate sub-holding to hold pharmacy premises (created Jul 2022) | Status not publicly disclosed |
Second new entity (Jul 2022) | Belgium | Created alongside Pharmasimple Immo to reflect pharmacy strategy; name not captured in sources reviewed | — |
Acquired pharmacies (up to 14 by Jul 2022) | Belgium (mostly rural) | Community pharmacies affiliated to the Pharmasimple banner | Several "retroceded" in early 2023; remainder fell into bankruptcy |
“—” = not publicly disclosed.
Revenue by Segment and Revenue by Segment (%)
| Segment (EUR Mn) | H1 2021 | H1 2022 |
|---|---|---|
E-commerce revenue | 15.9 | 10.8 |
Pharmacies (offline) revenue | 0 | 3.9 |
Total revenue (July 2022 revenue release) | 15.9 | 14.7 |
E-commerce share of total (%) | 100 | 73.5 |
Pharmacies share of total (%) | 0 | 26.5 |
E-commerce YoY growth (%) | — | -32.1 |
Revenue by Segment
| Segment (EUR Mn) | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
Online / e-commerce (incl. minor B2B) | 28.1 | 45.2 | 30.0 |
Pharmacies | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
Revenue (EUR Mn) | 19.0 | 16.8 | 28.1 | 45.2 | 30.0 | — |
Revenue growth YoY (%) | — | -11.6 | 67.3 | 60.8 | -33.6 | — |
EBITDA (EUR Mn) | — | — | -1.3 | 1.0 | -4.6 | — |
EBITDA margin (%) | — | — | -4.6 | 2.2 | -15.3 | — |
Net income (EUR Mn) | — | — | — | — | -8.9 | — |
Net margin, aggregator (%) | -7.15 | -14.25 | -11.07 | -3.27 | -29.9 | — |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Half-Yearly)
| Metric | H1 2020 | H2 2020 | H1 2021 | H2 2021 | H1 2022 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 30.2 | 15.1 | 15.9 | 14.1 | 13.6 |
Gross margin (% of revenue) | 14.5 | — | 10.8 | — | 20.0 |
Gross profit (EUR Mn) | — | — | — | — | 2.7 |
EBITDA (EUR Mn) | 1.4 | — | -1.7 | — | -3.6 |
Operating income (EUR Mn) | 0.3 | — | -2.9 | — | -6.0 |
Net income (EUR Mn) | 0.3 | — | -3.0 | — | — |
Net debt, end of period (EUR Mn) | — | 5.2 | 7.4 | 8.6 | 3.5 |
Cash, end of period (EUR Mn) | — | — | — | 1.1 | 3.6 |
Balance Sheet
| Metric | FY2020 | FY2021 | FY2022 | Mar 2023 |
|---|---|---|---|---|
Total assets (EUR Mn) | — | 18.2 | — | — |
Cash & equivalents (EUR Mn) | — | 1.1 | — | — |
Total debt (EUR Mn) | — | 14.0 | — | — |
Net debt (EUR Mn) | 5.2 | 8.6 | 0.8 | 1.0 |
Trade payables (EUR Mn) | — | 3.6 | 2.8 | 2.0 |
Shareholders' equity (EUR Mn) | 5.5 | 4.1 | 3.8 | 1.9 |
Balance Sheet (FY2019–FY2022)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Dividends paid (EUR Mn) | 0 | 0 | 0 | 0 |
Share buybacks (EUR Mn) | 0 | 0 | 0 | 0 |
Equity raised (EUR Mn) | 5.0 | — | — | — |
Shareholder bridge loans (EUR Mn) | 0.5 | — | — | — |
Convertible programme signed (EUR Mn) | — | — | 10.0 | — |
Loan signed (EUR Mn, Jan 2023) | — | — | — | 5.6 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2020 | FY2021 |
|---|---|---|
ROE (%) | — | -216 |
ROA (%) | — | -49 |
Current ratio (x) | — | 1.1 |
Quick ratio (x) | — | 0.8 |
Debt / equity (x) | — | 3.4 |
Solvency ratio, equity / assets (%) | — | 22.8 |
Net debt / EBITDA (x) | 5.2 | — |
Asset turnover (x) | — | 1.64 |
Revenue per FTE (EUR Mn) | — | 0.52 |
Region (% of Revenue) Overview
| Region (% of revenue) | FY2017 |
|---|---|
France (% of revenue) | 90 |
Belgium & other (% of revenue) | 10 |
Share Price History
| Date | Price (EUR) | Event | Source |
|---|---|---|---|
Nov 2016 | 7.50 | Direct listing price | Release 20 Mar 2017 |
15 Mar 2017 | 13.85 | +85% from listing | Release 20 Mar 2017 |
Jan–Oct 2021 | — | Stock down about 76% YTD by 8 Oct 2021 | Cercle Finance |
15 Mar 2023 | 0.275 | Post-consolidation line, +82% intraday | Zonebourse |
16 May 2023 | 0.013 | Last price at suspension | BFM Bourse |
2023 calendar year | — | –99.72% | Zonebourse |
Valuation Snapshot
| Metric | Value |
|---|---|
1-year share price performance | Not meaningful — suspended since 16 May 2023 |
3-year share price performance | Not meaningful (effectively –100%) |
5-year share price performance | Not meaningful (effectively –100%) |
P/E | Not meaningful (losses; bankrupt) |
Analyst consensus | No sell-side coverage identified |
Dividend history | No dividends ever paid |
Buyback authorisations | None disclosed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Not publicly disclosed; all claims now subject to bankruptcy ranking |
Formal delisting date | Not located in public sources; vendors show the instrument as inactive / no longer quoted |
Instrument by Date
| Date | Instrument | Amount (EUR Mn) | Counterparty |
|---|---|---|---|
Oct 2016 | Private placement | 1.0 | News Invest, Sopromec |
Sep 2017 | Placement with transfer to Euronext Growth | — | Four small-cap funds and others |
Jan 2019 | Shares + convertible bonds (acquisition consideration) | 3.9 (bond portion) | Enova Santé shareholders |
Dec 2019 | Capital increase | 5.0 | Existing shareholders; Willems group 2.32 |
Aug 2021 | OCABSA programme | 10.0 (maximum) | GTO 12 |
Jan 2023 | Loan | 5.64 | GTO 12 |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance. The last guidance (3 January 2023) called for roughly EUR 6M of 2023 revenue from pharmacies and operating profitability on continuing operations, with acquisitions to resume once total debt returned to about EUR 1M. This guidance lapsed with the bankruptcy. There is no consensus estimate and none will be produced.
Bull-case arguments (now essentially academic)
-
Creditor recoveries from asset sales. The estate may realise value from remaining pharmacy licences/goodwill and any real estate held via Pharmasimple Immo; Belgian pharmacy licences have historically commanded meaningful prices.
-
Litigation or recovery actions. Trustees could pursue claims (against directors or counterparties) that augment the estate, given the FSMA's findings on 2018–2019 conduct.
-
The franchise once had real traction. A business that reached EUR 45.2M of sales and 23.5M annual visits demonstrated consumer demand; the brands sold in 2022 may survive under new owners — but that value accrues to buyers, not to Pharmasimple shareholders.
Bear-case arguments (decisive)
-
Equity is worthless. With a single creditor claiming EUR 29.8M against last reported equity of EUR 1.9M, shareholders rank behind creditors in a liquidation and should expect zero recovery.
-
The disclosed financials are unreliable. The gap between reported net debt (EUR 0.8–1.0M) and the EUR 29.8M claim undermines any valuation built on company figures.
-
The model never generated sustainable profit. Only one positive EBITDA year (2020, 2.2% margin) in the listed history, and the online assets — the only scaled business — were sold.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Trustees' reports and claims verification in the Charleroi court | Determines creditor recoveries and the treatment of the GTO 12 claim |
| Any formal Euronext delisting notice | Clarifies the security's legal status for holders (tax loss crystallisation) |
| Criminal complaint outcome | Potential director-liability findings |
| Expiry of FSMA named publication (Dec 2026) | Procedural closure of the regulatory case |
| Any director-liability or clawback action by trustees | Only realistic source of additional estate value |
Analyst verdict
Pharmasimple is no longer an investable company; it is a bankruptcy estate. The dossier above should be read as a post-mortem.
The core lesson is that revenue growth in online parapharmacy was never matched by unit economics. Across 2017–2021 the company more than doubled its peak revenue through two French acquisitions and a pandemic windfall, yet produced positive EBITDA only once, at a margin of about 2%. Gross margins of 10–15% left no room for the marketing spend required to hold search-driven traffic once COVID demand faded, and the 2021 collapse — a net loss near 30% of sales — exhausted the balance sheet.
The response compounded the problem. Rather than shrink to a defensible niche, management pivoted to a capital-intensive pharmacy roll-up targeting 150–200 outlets, funded almost entirely by convertible bonds and loans from a single alternative financier. That structure made the company's survival contingent on one counterparty's continued willingness to fund. When Global Tech Opportunities 12 stopped in May 2023, insolvency followed within days, and the creditor's EUR 29.8M claim exposed how little the company's own "net debt" disclosures had told investors.
Governance failures run through the story. The FSMA's December 2025 decision found that the founder-CEO traded on inside information, supported the share price with offsetting orders and misled forum investors during the 2019 liquidity crisis, while failing to declare more than 1,700 transactions. The modest fines reflect the age of the facts and the founder's own losses, not the seriousness of the conduct.
For holders, recoveries should be assumed to be nil. For analysts of European micro-caps, Pharmasimple is a textbook case of the risks of founder-dominated issuers on growth markets, opaque debt reporting, and death-spiral convertible financing. Rating: not rated / equity value nil.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background |
|---|---|---|---|
Michael (Michaël) Willems | Co-founder; Chairman & CEO (PDG); director in his own name and permanent representative of AM Consultancy SRL, which held the delegated day-to-day management mandate | 2010 – bankruptcy (2023) | Master's degree in biotechnology and management (FSMA decision) |
Annabelle Willems | Co-founder | From 2010; later role not publicly disclosed | — |
Julien Mazerolle | CEO of Enova Santé since 2017; took a new group function after the 2019 acquisition | 2019 – not publicly disclosed | Ran 1001Pharmacies.com |
CFO (name not disclosed) | Directeur financier; FSMA contacted the CFO in August 2019 about undeclared managers' transactions | — | — |
SRIW representatives | Directors representing Walloon regional investor SRIW (via subsidiary Samanda SA); several successive permanent representatives | 2010s – not publicly disclosed | — |
Independent director nominated by Alpha Blue Ocean | Willems stated in a 2025–2026 interview that ABO wanted to appoint an independent director from January 2023, naming Jean Paul Michielsen | 2,023 | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Michael Willems + AM Consultancy, Junior Invest, Acacia | 10.90% before; 31.60% after the Dec 2019 capital increase | 4 Dec 2019 | FSMA decision |
SRIW (via Samanda SA) | Significant shareholder; exact % not publicly disclosed | 2019 | FSMA decision |
IMBC (Invest Mons-Borinage-Centre) | Public shareholder; % not publicly disclosed | 2019 | FSMA decision |
News Invest, Sopromec Participations | Early investors (2016); % not publicly disclosed | 2016 | FrenchWeb; Preqin |
Atout Capital | Listed by Preqin as an investor; % not publicly disclosed | — | Preqin |
Four small-cap investment funds | Subscribed around the Sept 2017 Euronext Growth transfer; names not captured | 2017 | Release 18 Aug 2017 |
Global Tech Opportunities 12 (Alpha Blue Ocean) | Holder of convertible bonds/warrants and loans; resulting equity stake not publicly disclosed; largest creditor (EUR 29.8M claim) | 2021–2023 | Releases; Business Wire |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning relative to Pharmasimple |
|---|---|---|
1001Pharmacies.com | French online parapharmacy | Named rival in 2016; acquired by Pharmasimple in 2019 |
Easyparapharmacie | French online parapharmacy | Named rival in 2016–2017; strong price positioning |
E.Leclerc (parapharmacy) | French mass-retail parapharmacy, online and offline | Named rival in 2016; vast store network and purchasing scale |
Redcare Pharmacy (formerly Shop Apotheke) / Newpharma | Belgian and European online pharmacy | Pan-European scale player with Belgian presence |
DocMorris | European online pharmacy | Scale player (primarily Germany) |
Cocooncenter | French online parapharmacy | Specialist e-tailer |
Pharmacie Lafayette | French pharmacy chain/network with online arm | Price-led omnichannel network |
Atida (Santé Discount) | French online parapharmacy | Specialist e-tailer |
Multipharma | Belgian cooperative pharmacy chain | Direct competitor to the 2022 pharmacy network |
Benu (Phoenix group) | Belgian pharmacy chain | Scale chain backed by a wholesaler |
Médi-Market | Belgian parapharmacy chain | Discount parapharmacy stores |
ComptoirSanté | French online parapharmacy | Cited in 2016 as having ceased operating — illustrates sector attrition |
Peer Comparison FY2021
| Metric | Pharmasimple (FY2020) | Pharmasimple (FY2021) |
|---|---|---|
Revenue (EUR Mn) | 45.2 | 30.0 |
Revenue growth (%) | 60.8 | -33.6 |
EBITDA margin (%) | 2.2 | -15.3 |
Recent Developments
The company has produced no operating news since its bankruptcy.



